Literature DB >> 26631136

Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats' disease.

Saemi Park1, Han Joo Cho2, Dong Won Lee1, Chul Gu Kim1, Jong Woo Kim1.   

Abstract

PURPOSE: To evaluate the efficacy of intravitreal bevacizumab injections combined with laser photocoagulation in the treatment of adult-onset Coats' disease.
METHODS: Thirteen eyes of 13 patients suffering from adult-onset Coats' disease were retrospectively included and analyzed. All patients were treated at baseline using intravitreal bevacizumab injections combined with laser photocoagulation. Follow-up treatment was performed as necessary.
RESULTS: The mean age of the subjects was 40.3 years, and the mean follow-up period was 24.8 months. The mean number of bevacizumab injections was 2.69, and the mean number of laser treatment sessions was 1.68. The mean baseline best-corrected visual acuity (BCVA) was 0.72 logarithm of the minimum angle of resolution (logMAR; 20/104 Snellen equivalent), while the mean BCVA at the final visit was 0.68 logMAR (20/95; P = 0.548). In three patients (23.0 %), BCVA had improved by more than 3 lines, and seven patients (54.0 %) showed stable BCVA (changes within 2 lines of visual acuity) after treatment. The mean central foveal thickness improved significantly, from 473 μm at baseline to 288 μm at the final visit (P = 0.023). Final BCVA was significantly correlated with a baseline BCVA (P < 0.001; ρ = 0.882). The final BCVA of patients who had subfoveal hard exudates at baseline was significantly worse than that of patients without such exudates (P = 0.005).
CONCLUSIONS: Intravitreal bevacizumab injection combined with laser photocoagulation may be an effective treatment option for adult-onset Coats' disease. Both poor initial BCVA and the occurrence of subfoveal hard exudates at baseline were associated with poor prognosis and poor therapeutic response.

Entities:  

Keywords:  Bevacizumab; Coat’s disease; Laser photocoagulation; Vascular endothelial growth factor

Mesh:

Substances:

Year:  2015        PMID: 26631136     DOI: 10.1007/s00417-015-3233-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  17 in total

1.  Use of intravitreal triamcinolone and bevacizumab in Coats' disease with central macular edema.

Authors:  Michael R R Böhm; Constantin E Uhlig
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-02-12       Impact factor: 3.117

2.  The effect of intravitreal bevacizumab in the treatment of Coats disease in children.

Authors:  Chun-Ju Lin; Jiunn-Feng Hwang; Yan-Ting Chen; San-Ni Chen
Journal:  Retina       Date:  2010-04       Impact factor: 4.256

3.  Coats' disease diagnosed in adulthood.

Authors:  Lindsay M Smithen; Gary C Brown; Alexander J Brucker; Lawrence A Yannuzzi; Christina M Klais; Richard F Spaide
Journal:  Ophthalmology       Date:  2005-06       Impact factor: 12.079

4.  Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab.

Authors:  Yu-Guang He; Hao Wang; Biren Zhao; Jason Lee; Dinesh Bahl; Jessica McCluskey
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-09       Impact factor: 3.117

5.  Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture.

Authors:  J A Shields; C L Shields; S G Honavar; H Demirci
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

6.  Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials.

Authors:  Amitha Domalpally; Michael S Ip; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2015-01-17       Impact factor: 12.079

7.  Vascular endothelial growth factor in Coats' disease.

Authors:  Qi Zhao; Xiao-Yan Peng; Feng-Hua Chen; Yong-Peng Zhang; Lian Wang; Qi-Sheng You; Jost B Jonas
Journal:  Acta Ophthalmol       Date:  2013-06-13       Impact factor: 3.761

8.  Manifestation of Coats' disease by age in Taiwan.

Authors:  Chien-Hsiung Lai; Hsi-Kung Kuo; Pei-Chang Wu; Ming-Lun Kuo; Yung-Jen Chen
Journal:  Clin Exp Ophthalmol       Date:  2007 May-Jun       Impact factor: 4.207

9.  ranibizumab in the management of advanced Coats disease Stages 3B and 4: long-term outcomes.

Authors:  Marie-Claire Gaillard; Assimina Mataftsi; Aubin Balmer; Susan Houghton; Francis L Munier
Journal:  Retina       Date:  2014-11       Impact factor: 4.256

10.  Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium.

Authors:  Young Sun; Atul Jain; Darius M Moshfeghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-03-07       Impact factor: 3.117

View more
  10 in total

1.  The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater.

Authors:  Yue-Zhu Lu; Guang-Da Deng; Jing-Hua Liu; Hong Yan
Journal:  Int J Ophthalmol       Date:  2018-06-18       Impact factor: 1.779

2.  Intravitreal bevacizumab injections combined with laser photocoagulation for adult-onset Coats' disease.

Authors:  Saemi Park; Han Joo Cho
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-07       Impact factor: 3.117

3.  Intravitreal Bevacizumab as an adjunct to laser in the management of adult onset Coats' disease.

Authors:  Neha Goel; Vinod Kumar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-27       Impact factor: 3.117

4.  Longitudinal characterization and treatment response of retinal arterial macroaneurysms in adult-onset coats disease.

Authors:  Amisha D Dave; Alisa T Thavikulwat; Tharindu De Silva; Henry E Wiley; Tiarnan D L Keenan; Wai T Wong; Catherine A Cukras
Journal:  Am J Ophthalmol Case Rep       Date:  2022-07-01

5.  Vitrectomy for a secondary epiretinal membrane following treatment of adult-onset Coats' disease.

Authors:  Ayman G Elnahry; Essam M Sallam; Kirollos J Guirguis; Joseph H Talbet; Ahmed A Abdel-Kader
Journal:  Am J Ophthalmol Case Rep       Date:  2019-07-09

6.  Optical Coherence Tomography Angiography Findings After Intravitreal Ranibizumab in Patients With Coats Disease.

Authors:  Gilda Cennamo; Daniela Montorio; Chiara Comune; Maria Paola Laezza; Matteo Fallico; Maria Elena Lionetti; Michele Reibaldi
Journal:  Front Med (Lausanne)       Date:  2021-01-21

7.  Clinical features and prognostic factors in 71 eyes over 20 years from patients with Coats' disease in Korea.

Authors:  Hyun Goo Kang; Jung Dong Kim; Eun Young Choi; Suk Ho Byeon; Sung Soo Kim; Hyoung Jun Koh; Min Kim
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

8.  The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats' disease.

Authors:  Longli Zhang; Yifeng Ke; Wei Wang; Xueying Shi; Kaiwen Hei; Xiaorong Li
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-03-16       Impact factor: 3.117

9.  Aqueous humour cytokines profiles in eyes with Coats disease and the association with the severity of the disease.

Authors:  Tingyi Liang; Yu Xu; Xiuyu Zhu; Xiang Zhang; Jing Li; Peiquan Zhao
Journal:  BMC Ophthalmol       Date:  2020-05-05       Impact factor: 2.209

10.  Vitrectomy and external drainage of subretinal fluid containing high concentration of vascular endothelial growth factor for advanced coats disease.

Authors:  Fukutaro Mano; Itsuka Matsushita; Hiroyuki Kondo; Shoko Utamura; Chiori Kondo; Shunji Kusaka
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.